• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Imunon Inc.

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNN alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 0)*

     

    IMUNON, INC.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    15117N503

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒ Rule 13d-1(b)
         
      ☐ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 15117N503

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ayrton Capital LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    1,054,438*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    1,054,438*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,054,438*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

     

     

     

     

    CUSIP No. 15117N503

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B

     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    1,054,438*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    1,054,438*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,054,438*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

     

     

     

     

    CUSIP No. 15117N503

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Waqas Khatri

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    1,054,438*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    1,054,438*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,054,438*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

     

    CUSIP No. 15117N503

     

    Item 1. (a). Name of Issuer:
         
        Imunon, Inc.
         
      (b). Address of issuer’s principal executive offices:
         
        997 Lenox Drive, Suite 100
        Lawrenceville, NJ 08648
         
         
    Item 2. (a). Name of person filing:
         
        Ayrton Capital LLC
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Waqas Khatri
         
        Address or principal business office or, if none, residence:
         
      (b). Ayrton Capital, LLC
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Suite #7, Grand Pavilion Commercial Centre
        802 West Bay Road
        Grand Cayman
        P.O. Box 10250
        Cayman Islands
         
        Waqas Khatri
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
      (c). Citizenship:
         
        Ayrton Capital LLC – Delaware
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – Cayman Islands
        Waqas Khatri – United States
         
      (d). Title of class of securities:
         
        Common Stock, $0.01 par value
         
      (e). CUSIP No.:
         
        15117N503

     

     

     

     

    CUSIP No. 15117N503

     

    Item 3. If This Statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
       
      Ayrton Capital LLC

     

      (a) ☐ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) ☐ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) ☐ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) ☒ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) ☐ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) ☐ Parent Holding Company or control person in accordance with § 240.13d-1(b)(ii)(G)
      (h) ☐ Savings Association as defined in § 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) ☐ Church plan that is excluded from the definition of an investment company under § 3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(ii)(J)
      (k) ☐ Group, in accordance with § 240.13d-1(b)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
        Ayrton Capital LLC – 1,054,438*(1)
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – 1,054,438*(1)
        Waqas Khatri – 1,054,438*(1)
         
      (b) Percent of class:
         
        Ayrton Capital LLC – 9.9%(2)
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – 9.9%(2)
        Waqas Khatri – 9.9%(2)
         
      (c) Number of shares as to which Ayrton Capital LLC has:

     

      (i) Sole power to vote or to direct the vote     1,054,438*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of     1,054,438*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Alto Opportunity Master Fund SPC – Segregated Master Portfolio B has:     ,
               
      (i) Sole power to vote or to direct the vote     1,054,438*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   1,054,438*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Waqas Khatri has:      
             
      (i) Sole power to vote or to direct the vote   1,054,438*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   1,054,438*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .

     

    *Shares reported herein represent Common Stock of Imunon, Inc. (the “Issuer”) held by Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman Islands exempted company (the “Fund”). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the “Investment Manager”), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the “Reporting Persons”).

     

     

     

     

    CUSIP No. 15117N503

     

    (1) Represents 1,054,438 shares of Common Stock issuable on the exercise of certain warrants (the “Warrants”) held by the Reporting Persons. The issuable shares of Common Stock are subject to a 9.99% beneficial ownership blocker.

     

    (2) Based on (i) 10,650,889 shares of Common Stock of the Issuer that were outstanding as of June 30, 2024; and (ii) 1,054,438 shares of Common Stock issuable on the exercise of the Warrants held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer’s Form 424B3, filed on September 27, 2024.

     

    For the sake of clarity, the holdings of the Reporting Persons reported herein are as of September 30, 2024.

     

    By virtue of these relationships (i.e., Mr. Khatri’s sole authority to direct the affairs of the Investment Manager, including the voting and disposition of shares of Common Shares held by all Reporting Persons), the Reporting Persons may be deemed to have sole voting and dispositive power with respect to the shares owned directly by the Fund. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the shares for purposes of Section 13 of the Act, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of the Reporting Person’s pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      Not applicable

     

     

     

     

     

    CUSIP No. 15117N503

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Not applicable
       
     Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to § 240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
      Not applicable
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 15117N503

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member of Ayrton Capital LLC
         
      Waqas Khatri
         
      By: /s/ Waqas Khatri

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see § 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. 15117N503

     

    Exhibit 1

     

    Joint Filing Statement

     

    Statement Pursuant to Rule 13d-1(k)(1)

     

    The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0.01 par value, of Imunon, Inc., beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    Dated: November 14, 2024 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member of Ayrton Capital LLC
         
      Waqas Khatri
       
      By: /s/ Waqas Khatri

     

     

     

    Get the next $IMNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMNN
    SEC Filings

    See more
    • Imunon Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Imunon, Inc. (0000749647) (Filer)

      5/20/25 7:00:28 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Imunon Inc.

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      5/19/25 8:20:49 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Imunon Inc.

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      5/13/25 6:10:57 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Anwer Khursheed

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/18/25 4:23:13 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fritz Frederick J.

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/18/25 4:22:09 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Braun Donald P

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/18/25 4:21:11 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      1/28/25 4:18:24 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Lindborg Stacy bought $24,500 worth of Imunon Common Stock (25,000 units at $0.98), increasing direct ownership by 10% to 264,166 units (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      8/16/24 8:03:50 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman of Board Tardugno Michael H bought $25,750 worth of Imunon Common Stock (25,000 units at $1.03), increasing direct ownership by 8% to 353,346 units (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      8/16/24 8:01:30 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $IMNN
    Financials

    Live finance-specific insights

    See more

    $IMNN
    Leadership Updates

    Live Leadership Updates

    See more

    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      11/14/24 5:37:34 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Imunon Inc.

      SC 13G/A - Imunon, Inc. (0000749647) (Subject)

      11/14/24 12:17:50 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      8/5/24 11:53:32 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

      First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian can

      5/12/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

      LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 12, 2025 to discuss financial results for the first quarter ended March 31, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IMNN-001 development program toward initiation of a Phase 3 clinical trial in advanced ovarian cancer. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or

      5/5/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

      First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesday, March 25, 2025, at 2:00 p.m. ET LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of its lead candidate IMNN-001 in development for the treatment

      3/24/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

      Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

      2/10/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

      Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

      5/8/24 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

      12/11/23 8:30:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

      Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications LAWRENCEVILLE, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced new data from its first Phase 1 proof-of-concept clinical trial of IMNN-101, an investigational DNA plasmid vaccine based on the Company's proprieta

      5/15/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

      First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian can

      5/12/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

      Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in oral presentation at 2025 ASCO Annual Meeting LAWRENCEVILLE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the first trial site has been initiated for the Company's Phase 3 pivotal study, called OVATION 3, of its le

      5/8/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care